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A B S T R A C T   
Several fatal bunyavirus infections lack specific treatment. Here, we show that diketo acids engage a panel of 
bunyavirus cap-snatching endonucleases, inhibit their catalytic activity and reduce viral replication of a taxo-
nomic representative in vitro. Specifically, the non-salt form of L-742,001 and its derivatives exhibited EC50 
values between 5.6 and 6.9 μM against a recombinant BUNV-mCherry virus. Structural analysis and molecular 
docking simulations identified traits of both the class of chemical entities and the viral target that could help the 
design of novel, more potent molecules for the development of pan-bunyavirus antivirals.   
The order Bunyavirales contains potentially fatal viruses that lack 
effective medical countermeasures. Many of them pose major public 
health threats and are pathogens prioritized in the World Health Orga-
nization (WHO) Blueprint for research and development (R&D) 
(Mehand et al., 2018). A hallmark is their segmented single-stranded 
RNA (ssRNA) genome with either negative or ambisense polarity. 
Thus, the synthesis of viral mRNA can be considered a limiting step in 
the early stages of the life cycle. The presence of 5′-capped extensions 
derived from the host mRNA in the viral transcripts suggests the use of a 
cap-snatching mechanism to initiate transcription. This mechanism was 
initially described for the Influenza virus (IFV) and although the specifics 
might vary between viruses, a constant feature is a metal dependent 
cap-snatching endonuclease (Cap-ENDO) responsible for the mRNA 
cleavage (Dias et al., 2009; Plotch et al., 1981; Reguera et al., 2016). 
Such viral enzymatic domain is essential for virus replication and pre-
sents a structurally conserved active site that can be exploited to 
generate broad-spectrum antivirals (Fernandez-Garcia et al., 2016; 
Reguera et al., 2010; Saez-Ayala et al., 2018; Song et al., 2016; Wang 
et al., 2020). 
Very few data are available about the activity of bunyaviral Cap- 
ENDO inhibitors, but structural studies of the target support the idea 
that chelating agents as the class of diketo acids (DKAs) could be 
addressed as starting points for the creation of drug-like candidates 
(Jones et al., 2019; Reguera et al., 2010; Saez-Ayala et al., 2018). In this 
study, we assessed the inhibitory scope of a series of DKA compounds 
(Fig. 1) against Cap-ENDOs from several bunyaviruses. These 
small-molecules have proven to be effective inhibitors of metal-
loenzymes like the Human Immunodeficiency virus 1 integrase (HIV-1 IN) 
and the IFV Cap-ENDO (Bacchi et al., 2011; Sechi et al., 2004; Stevaert 
et al., 2015), exerting their action through coordination to the bivalent 
metal ion(s) in the catalytic core of the enzymes. Particularly compound 
(8), also known as L-742,001, has demonstrated potent antiviral activity 
against IFV both in vitro and in vivo (Hastings et al., 1996; Nakazawa 
et al., 2008; Stevaert et al., 2015). It targets the two metal cofactors of 
the IFV Cap-ENDO via the DKA moiety while engaging crucial amino 
acids with its two aromatic “wings” (DuBois et al., 2012). Interestingly 
enough, although site-directed mutagenesis of residues associated to the 
active site of IFV Cap-ENDO leads to L-742,001 resistance, a single 
naturally emerging variant less susceptible to L-742,001 has been re-
ported after serial passage of IFV in the presence of this molecule 
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(Nakazawa et al., 2008; Song et al., 2016; Stevaert et al., 2013). Com-
pounds were obtained as previously reported (Bacchi et al., 2011; 
Maurin et al., 2004; Sanna et al., 2020; Sechi et al., 2004; Stevaert et al., 
2015). The synthetic routes and the chemical characterization are 
described in the supplementary data. 
A representative view of the compounds’ effect over the taxonomic 
order was gathered using the biochemically active Cap-ENDOs of 
evolutionary divergent viruses. The wild-type (WT) domains of La Crosse 
virus (LACV; LACV_L1-184_WT) and Rift Valley Fever virus (RVFV; 
RVFV_L1-248_WT) were expressed and purified. Meanwhile, due to dif-
ficulties in the production of Andes virus (ANDV) soluble WT protein, we 
chose mutant N167A (ANDV_L1-200_N167A) as the best candidate to 
screen for small-molecule inhibitors. In contrast to the WT, ANDV_L1- 
200_N167A can be expressed in bacteria, albeit retaining a considerable 
degree of nuclease activity. Residue 167 is located away from the cat-
alytic pocket and the putative substrate-binding groove (Fernandez--
Garcia et al., 2016). Proteins were produced as described in the 
supplementary data. To determine if the compounds were able to bind to 
the homologous enzymes, we measured the thermal stability of 
LACV_L1-184_WT, RVFV_L1-248_WT and ANDV_L1-200_N167A in the pres-
ence of 25 μM of the corresponding DKA either with 10 mM EDTA or 10 
mM MnCl2. Only in the presence of the divalent cations, the compounds 
were able to contribute to the stability of the proteins, which is common 
for chelators that bind mainly through coordination to the metal co-
factors. The highest increment to the melting temperature (Tm) in the 
presence of Mn2+ was observed with the addition of the prototype 
compound (8) and its salt L-742,001 hydrochloride (HCl), which raised 
the Tm (Δ Tm) by more than 5 ◦C in all Cap-ENDOs (Table 1; Fig. 2A). 
DKAs (8), (10), and (12) showed increments of the Tm bigger than the 
corresponding esters (9), (11), and (13), in accord with the higher 
complexing ability towards metal ions of the carboxyl group when 
compared to the ester group (Supplementary Fig. S1). Although the 
thermal shift assay (TSA) results might be in agreement with the ligands 
association constants, it can be misleading to rank compounds by their 
potency using the Δ Tm values (Lo et al., 2004; Pantoliano et al., 2001). 
Therefore, to evaluate the inhibitory capacity of DKAs, we further 
investigated the activity of all those that undoubtedly engaged the en-
zymes and exhibited a Δ Tm ≥ 3 ◦C. 
A FRET-based nuclease-monitoring assay was employed to deter-
mine the half maximal inhibitory concentration (IC50) of selected com-
pounds. Serial dilutions of the respective compounds were pre- 
incubated for 15 min with 0.25 μM of the proteins in a mixture con-
sisting of 50 mM Tris-HCl pH 7.5, 50 mM NaCl, 5% glycerol, 0.05 U/μl 
RNasin (Promega) and 10 mM MnCl2 or EDTA. The reactions were 
initiated by the addition of 1 μM of a 12mer poly(A) ssRNA substrate 
labeled at the 5′ end with fluorophore 6-FAM and the 3′ end with 
quencher BHQ-1 purchased from Biomers. The fluorescence signal was 
measured every 10 s for 20 min in a 96-well plate format at wavelengths 
490 nm and 515 nm for excitation and emission, respectively. The initial 
velocity of the reactions (V0) was determined as the slope of the linear 
phase of the progress curves, and the percentages of the enzymatic ac-
tivity were plotted against the concentrations of the compounds on a 
semilogarithmic graph. The IC50 of the compounds was calculated by 
nonlinear regression analysis performed using GraphPad Prism version 
7.00 (GraphPad Software, La Jolla California USA, www.graphpad. 
Fig. 1. Schematic representation of compounds (1)–(13); in bold the 
chelating region. 
Table 1 
DKAs induced stability of Bunyavirales Cap-ENDO’s and inhibitory potency.  













(1) 3.5 ± 0.5 4.9 ± 0.1 5.6 ± 0.2 24.9 ± 2.6 12.0 ± 1.7 2.8 ± 1.5 
(2) 4.9 ± 0.3 3.5 ± 0.5 4.9 ± 0.03 29.8 ± 3.7 16.2 ± 2.8 5.7 ± 2.3 
(3) 1.4 ± 0.01 1.4 ± 0.1 2.2 ± 0.1 NT NT NT 
(4) 2.2 ± 0.8 2.9 ± 0.1 2.5 ± 1 NT NT NT 
(5) 2.1 ± 0.2 1.9 ± 0.2 2.9 ± 0.1 NT NT NT 
(6) 3 ± 0.3 2.1 ± 0.1 2.2 ± 0.2 NT NT NT 
(7) 4.4 ± 0.1 3.2 ± 0.4 4.4 ± 0.3 31.0 ± 3.1 27.7 ± 4.1 11.1 ± 3.7 
L-742,001 HCl 6.3 ± 0.3 6.4 ± 1 6.1 ± 0.2 4.0 ± 0.5 7.2 ± 0.5 10.2 ± 0.8 
(8) 6.9 ± 0.9 6.1 ± 0.1 5.5 ± 0.3 7.3 ± 0.8 11.2 ± 1.7 13.9 ± 0.8 
(9) 1.6 ± 0.4 0.4 ± 0.1 1.7 ± 0.3 NT NT NT 
(10) 5 ± 0.8 4.1 ± 0.2 3.7 ± 0.6 13.7 ± 2.3 3.4 ± 0.5 11.9 ± 1.5 
(11) 3.8 ± 0.5 2.6 ± 0.3 1.6 ± 0.3 NT NT NT 
(12) 5.7 ± 0.1 4.3 ± 0.01 3.7 ± 0.1 11.4 ± 1.9 2.8 ± 0.5 11.4 ± 1.9 
(13) 1.2 ± 0.8 2.8 ± 0.1 2.5 ± 0.3 NT NT NT 
Δ Tm- The compound contribution to the enzyme thermal stability was determined by the difference in Tm between the samples containing MnCl2 in the presence and 
absence of the respective compound; IC50- The half-maximal inhibitory concentration was calculated by fitting the dose-response curves using a four parameter 
nonlinear regression; NT- Not tested. All data are mean ± standard deviation from 3 independent experiments. 
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com). (1) and its ester (2) as well as DKA (7) were able to suppress RVFV, 
ANDV and, to a lesser extent, also LACV Cap-ENDOs. Compounds (8) 
and its salt L-742,001 HCl, (10) and (12) were the most effective in-
hibitors of the RNA cleavage, displaying IC50 values within the lower μM 
range towards all the Cap-ENDOs tested (Table 1). As shown for com-
pound (8), all the DKAs tested had a similar dose-dependent effect over 
the catalytic activity of the different Cap-ENDOs (Fig. 2B). 
In agreement with our results, L-742,001 has also been reported to 
inhibit the Cap-ENDO of the Lymphocytic Choriomeningitis virus (LCMV) 
(Saez-Ayala et al., 2018). The enzymatic domain of this other bunya-
virus belongs to the subgroup of His - Cap-ENDOs, which characteris-
tically possess a substantially reduced activity and are suggested to be 
regulated differently as the His + Cap-ENDOs used in this study (Holm 
et al., 2018). Thus, to investigate the binding of L-742,001 to the 
different Cap-ENDOs, we performed a series of molecular docking 
experiments, using the available structures for LACV (PDB: 2XI7) and 
ANDV (PDB: 6Q99), and a homology model for RVFV (based on the 
TOSV Cap-ENDO structure; PDB: 6QVV). The results obtained indicate 
that, despite the overall structural similarity between the different 
Cap-ENDOs considered, the predicted L-742,001 binding region across 
the different proteins presents a degree of variability, both at a sequence 
and at a local structural level (Fig. 2C). Indeed, the main similarity is 
limited to the residues involved in the coordination of the Mn2+ ions. 
Overall, the binding site appears to be extensive and shallow. For this 
reason, there is a degree of variability in the binding of L-742,001 to the 
different enzymes. However, a common binding pattern, possibly indi-
cating a common pharmacophore of three features, seems to emerge: the 
key interaction of the DKA with the Mn2+ ions through the ß-ketoacid 
group is maintained across the different structures, and it follows the 
same chelation geometry as observed in the crystallized LCMV/L-742, 
Fig. 2. L-742,001 inhibitory molecular interactions with Bunyavirales Cap-ENDO’s. (A) Thermal stability of LACV_L1-184_WT (left panel), ANDV_L1-200_N167A 
(middle panel) and RVFV_L1-248_WT (right panel) in the presence of 10 mM EDTA (black dashed line), 10 mM EDTA plus 25 μM L-742,001 (green dashed line), 10 
mM MnCl2 (orange solid line) and 10 mM MnCl2 plus 25 μM L-742,001 (green solid line). The compound contribution to the stability of the proteins was determined 
by the difference in Tm between the samples containing MnCl2 in the presence and absence of L-742,001 (Δ Tm). The lines depict the non-linear fits of the normalized 
fluorescence curves to the Boltzmann equation. (B) Dose-dependent inhibition of the nuclease activity of LACV_L1-184_WT (red), ANDV_L1-200_N167A (blue) and 
RVFV_L1-248_WT (grey) by L-742,001. The reactions were initiated with the addition of 1 μM of FRET-labeled ssRNA substrate to the pre-incubated mixtures of 0.25 
μM of the respective enzymes with two-fold serial dilutions of L-742,001. The fluorescent signal arising from the substrate cleavage was measured using a Roche 
LightCycler 480 II at λex/λem = 490 nm/515 nm. The V0 of the reactions were used to calculate the percentage of activity at the different concentrations of the 
inhibitor. The dose-response curves were fit using a four parameter nonlinear regression. Δ Tm and half maximal inhibitory concentration (IC50) values are the mean 
and standard deviation from 3 independent experiments. Final 5% DMSO concentration was maintained in all assays to favor compound solubility. (C) Molecular 
docking results for L-742,001 on the Cap-ENDOs of LACV (PDB: 2XI7), ANDV (PDB: 6Q99), and RVFV (homology model). All results are shown from the same 
orientation centered on the Mn2+ ions (purple), and display the similarities in the predicted binding between the different Cap-ENDOs. The hydrophobic contact area 
of a defined sub-pocket is represented in green. 
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001 complex; a common hydrophobic sub-pocket can be identified in 
the binding pocket, occupied by the chlorobenzyl ring of L-742,001 in 
all results obtained from the molecular docking as well as in the complex 
structure with LCMV domain (Supplementary Fig. S2); the tertiary 
amine of L-742,001 establishes a clear interaction respectively with 
Asp45 of the LACV Cap-ENDO and with Glu54 of the ANDV Cap-ENDO, 
while sits in the proximity of Asp62 in the RVFV Cap-ENDO model – all 
these three acidic residues are also involved in the coordination of an 
Mn2+ ion. These observations could potentially be exploited in the 
design of a novel series of more potent, broad-spectrum, Cap-ENDO 
inhibitors. 
Having confirmed the inhibitory effect of L-742,001 and its salt L- 
742,001 HCl against a diverse set of bunyaviral Cap-ENDOs in enzy-
matic assays, we studied its ability to reduce viral replication in a cell- 
based assay. The antiviral activity against Bunyamwera virus (BUNV)- 
mCherry of L-742,001 HCl, L-742,001 and derivatives were evaluated in 
A549 cells (Shi et al., 2010). BUNV is considered a prototypic bunya-
virus and is used as a model for research of pathogens within Bunya-
virales. Serial dilutions of compounds were added followed by infection 
with 500 CCID50 of virus. At 4 days post infection (dpi) cells were 
stained with a 2.5 μg/ml Hoechst solution and high content imaging 
analysis was performed on the Arrayscan XTI from Thermofisher® using 
a custom protocol based on the SpotDetector BioApplication (Cello-
mics® software). The cell nuclei were detected using a dynamic 
threshold method based on differences in intensity peaks and the 
mCherry signal spots were detected by using a fixed intensity threshold 
based on the images acquired from the mCherry positive control 
(Fig. 3B). EC50 values are defined as the compound concentration that 
reduces the number of mCherry signal spots by 50% compared to the 
virus control (Fig. 3C). CC50 values are defined as the compound con-
centration that reduces the number of cells based on the nuclei by 50% 
compared to the virus control. In addition, we assessed the effect of the 
compounds on virus yield by RT-qPCR. Per reaction, a 20 μl RT-qPCR 
mix was prepared containing 4 μl of viral RNA with 600 nM and 900 
nM of FW and REV primers, respectively (FW: 
5′-ACACCACTGGGCTTAG-3′, REV: 5′-CAGCCCCCAAGGTTA-3′). For 
absolute quantification, standard curves were generated using 10-fold 
dilutions of template DNA of known concentration. 
L-742,001 HCl inhibited BUNV-mCherry in a dose-dependent 
manner with EC50 values of 10.6 ± 1.6 μM and 18.5 ± 1.6 μM, as 
determined by high content imaging and RT-qPCR, respectively, with no 
cytotoxicity for the host cell (CC50 > 100 μM) (Fig. 3A). A similar profile 
was observed with the derivatives of L-742,001, both esters and car-
boxylic acids. Their EC50 is slightly lower than L-742,001 HCl, but 
although comparable to that of the parent non-salt form (Table 2). Un-
expectedly, albeit presenting equivalent 1H-NMR spectra (Supplemen-
tary Fig. S3), we observed higher cytotoxicity for the non-salt form of L- 
742,001 HCl. 
Fig. 3. L-742,001 in vitro antiviral activity against Bunyaviruses. (A) Effect of L-742,001 HCl on BUNV-mCherry replication in A549 cells. Viral mCherry signal spots 
(black bars) and cell viability (solid circles) were determined using high-content imaging analysis (n = 7). Viral RNA yield (white bars) were determined by RT-qPCR 
(n = 5). All data are mean ± standard deviation. (B) Representative images acquired through high content imaging of virus control (VC), cell control (CC). (C) 
Representative images acquired through high content imaging of BUNV-mCherry infected cells treated with a serial dilution of L-742,001 HCl. Images represent one 
out of nine fields acquired per well. 
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In summary, our results demonstrate that the Cap-ENDO of bunya-
viruses is a valid target for the development of broad-spectrum antivirals 
and that the DKAs class of compounds contains chemical features worth 
exploring in the design of novel inhibitors. We have documented the 
biochemical inhibition of several bunyaviral Cap-ENDOs by different 
DKAs and have confirmed that for a group of them, this translates to a 
modest antiviral activity as observed in the reduction of the number of 
mCherry spots and the viral RNA yield of the recombinant BUNV- 
mCherry virus. Moreover, our molecular docking simulations have 
provided us with some valuable information on the interaction of L- 
742,001 with this viral enzyme, defining a possible basic common 
pharmacophore for a broad-spectrum class of Cap-ENDO inhibitors. 
From these results, more potent and selective molecules with a wide 
range of action can now be designed. Hence, bringing us one step closer 
to a pan-bunyavirus antiviral. 
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Table 2 
Antiviral activity, viral yield, cytotoxicity and selectivity of L-742,001 HCl, L- 














10.6 ± 1.6 18.5 ± 7.6 >100 >9.4 
(8) 5.6 ± 1.8 6.6 ± 3.0 12.2 ± 2.9 2.2 
(9) 6.9 ± 1.3 4.1 ± 0.4 11.2 ± 2.0 1.6 
(10) 6.3 ± 1.1 12.3 ± 2.2 55.5 ± 13.1 8.8 
(12) 6.3 ± 1.1 8.5 ± 0.5 42.7 ± 7.7 6.8 
(13) 6.8 ± 2.0 9.7 ± 1.3 22.6 ± 3.4 3.3 
EC50- half-maximal effective concentration; CC50- half-maximal cytotoxicity 
concentration. Antiviral activity and cytotoxicity were determined by high 
content imaging analysis (n = 6). Viral yield was determined by RT-qPCR (n =
3). All values, with exception of the selectivity index, are expressed as mean ±
standard deviation. 
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